|
|
 |
|
Viewing report
|
|
|
|
The Pharmaceutical Market: Poland
Espicom Business Intelligence Ltd, Sep 2009, Pages: 68
This in-depth pharmaceutical market report is ideal for executives wanting to understand the key drivers in pharmaceutical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national data projections, market outlook and key developments such as regulation, pricing/reimbursement, intellectual property, health facilities and government policy. The report also provides extensive background information, population trends, health status, health expenditure, organisation & administration, hospital services, medical personnel, healthcare development, market access information, trade data for raw materials and finished products and essential industry contacts. Included with the report are 3 free quarterly updated outlook reports, enabling you to keep up to date with market developments for a year.
Executive Summary
The Republic of Poland is bordered by Kaliningrad, Lithuania, Belarus, Ukraine, Germany, the Czech Republic and Slovakia. It was one of the ten countries to join the EU in May 2004. The Polish population stands at 38.1 million in 2009. Nearly 13% of residents are aged 65 years or over.
Issues still exist with regards to patent protection and data exclusivity, due to the often premature registration of generic pharmaceutical products. The United States Trade Representative listed Poland on its Special 301 Report Watch List in 2008.
In 2008, the Polish market for pharmaceuticals was estimated at US$7,410 million, or US$194 per capita. It is expected that the market will continue to expand at a rate of 6.0% per annum. This will take the Polish market to US$9,918 million, equal to US$261 per capita, by 2013.
Around 66% of the pharmaceutical market is supplied by imports. Germany and France were the leading suppliers in 2006, accounting for over 30% of imports. Domestic production tends to concentrate on the generics market.
Many of the state-owned ‘Polfas’ have now been bought out by foreign companies. Jelfa was taken over by Sanitas of Lithuania in April 2006. The US company IVAX, which was itself acquired by Teva in early 2006, purchased Polfa Kutno in December 2004. The Polish Pharmaceutical Holding is looking to sell Polfa Pabianice, Polfa Warsaw and Polfa Tarchomin by the end of 2009.
Customers who bought this item also bought
The Medical Device Market: Poland
The Pharmaceutical Market: Thailand
The Pharmaceutical Market: Morocco
The Pharmaceutical Market: Mexico
The Pharmaceutical Market: Ireland
The Pharmaceutical Market: Switzerland
The Pharmaceutical Market: Romania
The Pharmaceutical Market: Philippines
The Pharmaceutical Market: Saudi Arabia
Pharmaceutical and Healthcare Market in Poland 2009 - Development Forecasts for 2009-2011
The Pharmaceutical Market: Indonesia
The Pharmaceutical Market: Singapore
|
|
|
|
